GYN-AIDE: Gynecologic Oncology Navigation Through AI-Driven Education
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- University of Southern California
- Study ID
- NCT07279571
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Non-Interventional Study — OTHERNon-interventional study
Study Details
This study seeks to understand how endometrial cancer patients get medical information about cancer care and their satisfaction with those health-seeking methods. It also assesses patient interest in using an artificial intelligence educational resource.
Key Dates
- Start date
- Dec 31, 2026
- Status verified
- May 2026
- Primary completion
- Jun 9, 2027
- Completion
- Jun 9, 2028
Study Design
- Enrollment
- 48 participants (estimated)
Arms
- Arm: ObservationalPatients complete a survey on study.
Primary Outcome Measure
Current medical resources used by patients and perceived relative importance of those resources [ Time Frame: Up to 1 year ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Los Angeles General Medical Center | Los Angeles | California | 90033 | Xiaoyue M. Guo Xiaoyue M. Guo (PRINCIPAL_INVESTIGATOR) |
| USC / Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Xiaoyue M. Guo Xiaoyue M. Guo (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Los Angeles, CA
By condition
By specialty
Related Studies
- Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsPHASE1/PHASE2 · Recruiting · Children's Oncology Group · Birmingham, Alabama
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationRecruiting · Guardant Health, Inc. · Birmingham, Alabama
- A Beta-only IL-2 ImmunoTherapY StudyPHASE1/PHASE2 · Recruiting · Medicenna Therapeutics, Inc. · San Diego, California
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or CarcinosarcomaPHASE3 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama